A Phase 1b Dose-escalation Study of the Safety and Pharmacokinetics of Fixed-dose PCS6422 With Escalating Doses of Capecitabine Administered Orally to Patients With Advanced, Refractory Gastrointestinal Tract Tumors
Latest Information Update: 14 Jun 2024
At a glance
- Drugs Capecitabine (Primary) ; Eniluracil (Primary)
- Indications Gastrointestinal cancer
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors Processa Pharmaceuticals
- 11 Jun 2024 According to a Processa Pharmaceuticals media release, from this Phase 1b trial, we have been able to define the MTD and the RP2DR to use in our Phase 2 Optimal Dosage Regimen trial in breast cancer in the third quarter of 2024.
- 11 Jun 2024 Results presented in a Processa Pharmaceuticals Media Release.
- 10 Jun 2024 Planned End Date changed from 10 Mar 2024 to 10 Aug 2024.